GlobeNewswire: ICC International Cannabis Corp. Contains the last 10 of 126 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:47:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/12/18/1962240/0/en/International-Cannabis-Applies-for-Voluntary-Delisting-from-Canadian-Securities-Exchange.html?f=22&fvtc=4&fvtv=48103International Cannabis Applies for Voluntary Delisting from Canadian Securities Exchange2019-12-18T14:00:00Z<![CDATA[VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) reports that it has applied to voluntarily delist the Company’s Common Shares (“Shares”) from the Canadian Securities Exchange (the “CSE” or the “Exchange”).]]>https://www.globenewswire.com/news-release/2019/11/13/1946083/0/en/International-Cannabis-Provides-Transaction-Guidance.html?f=22&fvtc=4&fvtv=48103International Cannabis Provides Transaction Guidance2019-11-13T08:05:00Z<![CDATA[VANCOUVER, British Columbia, Nov. 13, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) reports that it has agreed to terminate the transactions relating to the purchase of Wayland Group Corp.’s (“Wayland”) international portfolio of cannabis assets, licenses and operations pursuant to a termination agreement dated October 11, 2019 (the “Termination Agreement”). Pursuant to the Termination Agreement, ICC will relinquish its right to acquire Wayland's international asset portfolio and Wayland will return the 246,613,995 common shares in the capital of ICC it previously received pursuant to the definitive agreement between both parties dated April 22, 2019. The Termination Agreement also provides that Wayland will retain certain assets previously transferred from Wayland to ICC, together with a mutual release.]]>https://www.globenewswire.com/news-release/2019/07/23/1886420/0/en/REPEAT-Pfizer-Bristol-Myers-Squibb-and-Biogen-Advisor-Dr-Alex-Makriyannis-PhD-Joins-ICC-Funded-Biosynthesis-Cannabinoid-Company-to-Champion-Cannabinoid-Pharmaceutical-Research-and-.html?f=22&fvtc=4&fvtv=48103REPEAT - Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alex Makriyannis, PhD, Joins ICC Funded Biosynthesis Cannabinoid Company; to Champion Cannabinoid Pharmaceutical Research and THC/CBD Edibles Application Mandates2019-07-23T12:30:00Z<![CDATA[VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) is pleased to announce that the Company, alongside Biotii Technologies Corp. (“Biotii”) has entered into a cannabinoid pharmaceutical advisory agreement (the “Agreement”) with Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alexandros Makriyannis, PhD (“Dr. Makriyannis”). A professor of Chemistry and Chemical Biology in the Department of Medicinal Chemistry at Northeastern University, Dr. Makriyannis is credited with numerous scientific cannabinoid-centric achievements, including the discovery of cannabinoid receptor antagonists, as well as pioneering inmetabolically stable endocannabinoids.]]>https://www.globenewswire.com/news-release/2019/07/23/1886142/0/en/Pfizer-Bristol-Myers-Squibb-and-Biogen-Advisor-Dr-Alex-Makriyannis-PhD-Joins-ICC-Funded-Biosynthesis-Cannabinoid-Company-to-Champion-Cannabinoid-Pharmaceutical-Research-and-THC-CBD.html?f=22&fvtc=4&fvtv=48103Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alex Makriyannis, PhD, Joins ICC Funded Biosynthesis Cannabinoid Company; to Champion Cannabinoid Pharmaceutical Research and THC/CBD Edibles Application Mandates2019-07-23T04:05:00Z<![CDATA[VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) is pleased to announce that the Company, alongside Biotii Technologies Corp. (“Biotii”) has entered into a cannabinoid pharmaceutical advisory agreement (the “Agreement”) with Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alexandros Makriyannis, PhD (“Dr. Makriyannis”). A professor of Chemistry and Chemical Biology in the Department of Medicinal Chemistry at Northeastern University, Dr. Makriyannis is credited with numerous scientific cannabinoid-centric achievements, including the discovery of cannabinoid receptor antagonists, as well as pioneering inmetabolically stable endocannabinoids.]]>https://www.globenewswire.com/news-release/2019/07/18/1884548/0/en/REPEAT-International-Cannabis-to-Supply-New-Zealand-s-NUBU-Pharmaceuticals-With-Portfolio-of-Full-Spectrum-Pharmaceutical-THC-CBD-Products.html?f=22&fvtc=4&fvtv=48103REPEAT - International Cannabis to Supply New Zealand’s NUBU Pharmaceuticals With Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products2019-07-18T12:00:00Z<![CDATA[VANCOUVER, British Columbia, July 18, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”).]]>https://www.globenewswire.com/news-release/2019/07/18/1884346/0/en/International-Cannabis-to-Supply-New-Zealand-s-NUBU-Pharmaceuticals-With-Portfolio-of-Full-Spectrum-Pharmaceutical-THC-CBD-Products.html?f=22&fvtc=4&fvtv=48103International Cannabis to Supply New Zealand’s NUBU Pharmaceuticals With Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products2019-07-18T04:05:00Z<![CDATA[VANCOUVER, British Columbia, July 18, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”).]]>https://www.globenewswire.com/news-release/2019/06/18/1870235/0/en/REPEAT-International-Cannabis-Completes-Technical-Feasibility-Study-for-Danish-GACP-EU-GMP-Certified-Greenfield-Cultivation-and-Processing-Facility-Forecasted-2021-Production-of-Ci.html?f=22&fvtc=4&fvtv=48103REPEAT - International Cannabis Completes Technical Feasibility Study for Danish GACP/EU-GMP Certified Greenfield Cultivation and Processing Facility; Forecasted 2021 Production of Circa 20,000,000 Grams of Dried Flower2019-06-18T12:00:00Z<![CDATA[VANCOUVER, British Columbia, June 18, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) is pleased to announce that the Company has completed a Technical Feasibility Study (the “Feasibility Study”) relating to its proposed 150,000 square foot Danish GACP/EU-GMP certified Greenfield cultivation, processing and manufacturing facility (the “Danish Facility”).]]>https://www.globenewswire.com/news-release/2019/06/18/1869978/0/en/International-Cannabis-Completes-Technical-Feasibility-Study-for-Danish-GACP-EU-GMP-Certified-Greenfield-Cultivation-and-Processing-Facility-Forecasted-2021-Production-of-Circa-20-.html?f=22&fvtc=4&fvtv=48103 International Cannabis Completes Technical Feasibility Study for Danish GACP/EU-GMP Certified Greenfield Cultivation and Processing Facility; Forecasted 2021 Production of Circa 20,000,000 Grams of Dried Flower2019-06-18T05:28:59Z<![CDATA[VANCOUVER, British Columbia, June 18, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) is pleased to announce that the Company has completed a Technical Feasibility Study (the “Feasibility Study”) relating to its proposed 150,000 square foot Danish GACP/EU-GMP certified Greenfield cultivation, processing and manufacturing facility (the “Danish Facility”).]]>https://www.globenewswire.com/news-release/2019/06/13/1868333/0/en/REPEAT-International-Cannabis-Strengthens-Colombian-Pharmacy-Portfolio-Within-LATAM-Distribution-Footprint-Provides-Guidance-on-Expansion-Strategy.html?f=22&fvtc=4&fvtv=48103REPEAT - International Cannabis Strengthens Colombian Pharmacy Portfolio Within LATAM Distribution Footprint; Provides Guidance on Expansion Strategy2019-06-13T12:00:00Z<![CDATA[VANCOUVER, British Columbia, June 13, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) is pleased to announce it has entered into a definitive agreement to acquire 100 per cent of Grupo Pharma Colombiano Inc. (“Grupo Pharma”), further augmenting its LATAM pharmacy distribution network.]]>https://www.globenewswire.com/news-release/2019/06/13/1868134/0/en/International-Cannabis-Strengthens-Colombian-Pharmacy-Portfolio-Within-LATAM-Distribution-Footprint-Provides-Guidance-on-Expansion-Strategy.html?f=22&fvtc=4&fvtv=48103International Cannabis Strengthens Colombian Pharmacy Portfolio Within LATAM Distribution Footprint; Provides Guidance on Expansion Strategy2019-06-13T04:05:00Z<![CDATA[VANCOUVER, British Columbia, June 13, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (the “Company” or "ICC" or “International Cannabis”) is pleased to announce it has entered into a definitive agreement to acquire 100 per cent of Grupo Pharma Colombiano Inc. (“Grupo Pharma”), further augmenting its LATAM pharmacy distribution network.]]>